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38 Poster Session Icount (\150K/ul) was the only significant predictor when the anal-
ysis was restricted to NHL patients mobilized with chemotherapy
(odds ratio 8.9, p\ 0.001). Conclusions: A significant proportion
(18%) of patients with NHL fails to mobilize stem cells. Use of fil-
grastrim without chemotherapy was associated with high failure
rate, but this needs to be confirmed in a larger comparative study.
For patients who were mobilized with chemotherapy, low platelet
count is the most significant predictive factor.
Univariate Analysis in Patients with NHL
N N Failed % Fail OR1 95% CI2 pPlatelet Count
\150 K 34 14 41
$150 K 107 12 11 0.2 0.1–0.4 \0.001Cellularity
\30% 44 13 30 2.7 1.1–6.5 0.02
$30% 97 13 13Regimen
Ifos/VP16 96 12 13
G-CSF alone 13 8 62 11.2 3.1–40 \0.001
Cyclophosphamide 14 3 21 1.9 0.5–7.8 0.4Other 18 3 17 1.4 0.3–5.6 0.61Odds Ratio.
2Confidence Interval.97
POSITRON EMISSION TOMOGRAPHY IDENTIFIES A DIFFERENTIAL
PATTERN OF BONE MARROW FDG UPTAKE IN ‘‘POOR’’ AND ‘‘GOOD’’
PERIPHERAL STEM CELL MOBILIZERS
Marcacci, G.1, Caraco`, C.2, D’Arena, G.1, Aloj, L.2, Corazzelli, G.1,
Frigeri, F.1, Lastoria, S.2, Pinto, A.1 1National Cancer Institute ‘‘Fon-
daz. Pascale’’, Naples, Italy; 2National Cancer Institute ‘‘Fondaz. Pas-
cale’’, Naples, Italy.
The use of prophylactic G-CSF is associated to the increase of
bone marrow (BM) fluorodeoxyglucose (FdG) uptake as detected
by Positron Emission Tomography (PET). In contrast, no data is
available as to changes in BM FdG-uptake during peripheral blood
stem cell (PBSC) mobilization. This study was aimed at investigat-
ing patterns of BMFdGuptake duringmobilization as quantified by
Standardized Uptake Value (SUV) determinations. We also evalu-
ated whether PET scanning may turn of value for identifying good
and poor mobilizers. To our knowledge this is the first PET-based
study in this setting. Methods Seventeen patients(pts)(M/F 5 10/
7), median age 51 yrs (r 28–65), with relapsed lymphoma (NHL/
HD5 13/4) without BM involvement, were accrued after informed
consent. Baseline PET was obtained at relapse, before salvage ther-
apy and anyCSF administration. After salvage regimes pts weremo-
bilized by VRL/CTX or ARA-C; G-CSF (10 mg/kg/d) was given
from day 16 through apheresis. PET scans were obtained on day
19 or 110 (after nadir with a WBC . 1000/ml). SUVmax and av-
erage (avg) were measured (whole lumbar spine and bilateral iliac
regions) and compared to SUV of the same BM regions at baseline
PET. The aim was to calculate a BM specific D-SUV (mobilizing vs
steady-state D-SUV) for each single patient. ResultsTwelve pts mo-
bilized PBSC (median CD34 peak 39.99/ml, r 23.28–280.58/ml; me-
dian CD34 in the harvest 3.3 106/Kg, r 2.1–12.5) while 5 pts were
poor mobilizers (median CD34 peak 10.9/ml, r 7.5–14.1/ml). In the
group of good mobilizers, apheresis was performed at CD34 peak
(day 111,114), with a median of 1 apheresis/pt (r 1–2). Unexpect-
edly, effective mobilization was associated with a low BM uptake of
FdG: median BM D-SUVmax and D-SUVavg of 2.0 (r 1.0–3.8) and
2.3 (r 0.9–3.9), respectively. In contrast, poor mobilizers displayed
a median D-SUVmax and D-SUVavg of 4.7 (r 2.4–12.8) and 5.9
(r 4.1–14.2), respectively.
Conclusions: While FdG-BM uptake usually increases upon
CSF administration, our results suggest that PBSC mobilization
may be associated with a more complex metabolic pattern of BM
as detected by PET. We documented that, 48 to 72 hrs beforeCD34 peak, poor mobilizers display a higher FdG-BM uptake
(D-SUV . 3) as compared to good mobilizers (D-SUV\ 3). These
preliminary results indicate that BM PETmay represent a new tool
for early identification of poor mobilizers allowing a timely modifi-
cation of the mobilization strategy to possibly rescue the procedure.98
RADIO-IMMUNOTHERAPY FOR LOW GRADE NON-HODGKIN’S LYM-
PHOMAMAY IMPAIR THE ABILITY TOMOBILIZE AUTOLOGOUS PERIPH-
ERAL BLOOD STEM CELLS
Raptis, A., Mapara,M., Bilodeau, A., Hornyak,M., Agha,M.E. UPMC
Cancer Centers/University of PittsburghMedical Center, Pittsburgh, PA.
High dose chemotherapy and autologous stem cell transplanta-
tion (ASCT) is a proven effective treatment modality for patients
with relapsed non-Hodgkin’s lymphoma. Radioimmunotherapy
(RIT) with 90Y-ibritumomab tiuxetan has been shown to be useful
in patients with relapsedNHL, but is now being used in the upfront
setting for patients with low gradeNHL, as some protocols now of-
fer abbreviated chemotherapy courses followed by RIT. As patients
relapse high dose therapy and ASCT become a valuable option but
the effect of RIT on the stem cell collection becomes an important
issue. We report four patients with follicular NHL who relapsed
within 6–8 months after RIT were treated with salvage chemother-
apy then mobilized with Cyclophosphamide and G-CSF. Two pa-
tients were heavily pre-treated for multiple relapses, but two had
only one relapse following upfront RIT. Only 2/4 patients mobi-
lized successfully, but with low yield. One of the patients developed
secondary leukemia, 6 months after ASCT. Surprisingly, the mobi-
lization failure patients were young, not heavily treated (had 6–7 cy-
cles of chemotherapy including the upfront and salvage therapy), no
exposure to external beam radiotherapy, but had heavy tumor bur-
den at initial presentation. Our results suggest that mobilization
failure following RIT is much higher that would have been pre-
dicted. Caution should be exercised when offering RIT to patients
with bulky disease low grade lymphoma as part of the upfront ther-
apy, as rapid relapsesmay not be salvageable with high dose therapy,
given the high rate of mobilization failure even in patients who are
not heavily treated. The long term safety of RIT andmyelodysplasia
in such patients is also an important concern, given the short inter-
val of tAML in our patient.99
PREDICTORS OF OUTCOME OF MANTLE CELL LYMPHOMA IN PATIENTS
WITH PROGRESSIVE DISEASE FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANTATION (ASCT)
Al-Farsi, K., Nagy, T., Keating, A., Crump, M., Kuruvilla, J. Princess
Margaret Hospital, Toronto, ON, Canada.
Introduction: Mantle Cell Lymphoma (MCL) is a subgroup of
malignant lymphomas that is considered incurable with conven-
tional therapy.While ASCT has improved progression free survival
(PFS), relapse remains a major issue. For patients (pts) who relapse
after ASCT, there is little information on the predictors of outcome
and optimal treatment strategy. We reviewed pts with progressive
disease following ASCT in an attempt to identify predictors of sub-
sequent outcome.Method:We retrospectively reviewed our com-
puterized database and charts of pts undergoing ASCT from May
1987 - Jul 2006. Of 47 pts, 21 relapsed after ASCT; 20 had adequate
data on subsequent therapy and were analyzed for factors influenc-
ing progression free survival (PFS) and overall survival (OS) using
Kaplan-Meier and Cox-Proportional Hazards analyses. Results:
Pt characteristics: At relapse post-ASCT, median age was: 56 years
(range 40–69). Stage 3 or 4: 16. High LDH: 8. Disease status of
ASCT: CR1/PR1 5 9, .CR1/PR1 5 11. IPI scores: low (n 5 9),
low-intermediate (n 5 8), high-intermediate (n 5 2) and high
(n 5 1). FLIPI scores: low (n 5 10), intermediate (n 5 4) and
high (n 5 6). Seven had bone marrow involvement, 3 had involve-
ment of peripheral blood and 5 had splenomegaly. Eighteen pts re-
ceived subsequent treatment: R-FCM: 4, Rituximab: 1, Radiation
